Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Isolation and characterization of Saccharomyces cerevisiae mutants with enhanced resistance to the anticancer drug bleomycin.

Current genetics - 1 May 2004

Aouida Mustapha, Tounekti Omar, Leduc Anick, Belhadj Omrane, Mir Lluis, Ramotar Dindial

Abstract excerpt

Bleomycin is an antitumor agent believed to act by damaging DNA. It is currently used for treating testicular carcinomas, but other types of cancers such as ovarian and colon are resistant to the drug from the outset. The mechanism involved in allowing cells to confer resistant to bleomycin is not known. We exploited the power of yeast genetics to isolate for the first time several bleomycin-resistant mutants...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Bleomycin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Microbial

Share to Electrophoresis, Polyacrylamide Gel

Share to Gene Expression Regulation, Fungal

Share to Hydrogen-Ion Concentration

Share to Microscopy, Fluorescence

Share to Transcriptional Activation

Source

Identifiers

PMID: 15007625
DOI: 10.1007/s00294-004-0492-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Isolation and characterization of Saccharomyces cerevisiae mutants with enhanced resistance to the anticancer drug bleomycin.PMID 15007625Read ↗

The Saccharomyces cerevisiae IMP2 gene encodes a transcriptional activator that mediates protection against DNA damage caused by bleomycin and other oxidants.Semantic proximity Read ↗

A genome-wide screen in Saccharomyces cerevisiae reveals altered transport as a mechanism of resistance to the anticancer drug bleomycin.Semantic proximity Read ↗

An allele of the yeast RPB7 gene, encoding an essential subunit of RNA polymerase II, reduces cellular resistance to the antitumor drug bleomycin.Semantic proximity Read ↗

Overexpression of genes involved in vesicular trafficking to the vacuole defends against lethal effects of oxidative damage.Semantic proximity Read ↗

A Saccharomyces cerevisiae mutant defines a new locus essential for resistance to the antitumour drug bleomycin.Semantic proximity Read ↗

Integrating genetic approaches into the discovery of anticancer drugs.Semantic proximity Read ↗

Saccharomyces cerevisiae as a model system to study the response to anticancer agents.Semantic proximity Read ↗

Disruption of the Saccharomyces cerevisiae cell-wall pathway gene SLG1 causes hypersensitivity to the antitumor drug bleomycin.Semantic proximity Read ↗

Yeast mutants as a model system for identification of determinants of chemosensitivity.Semantic proximity Read ↗

Using yeast to study resistance to topoisomerase II-targeting drugs.Semantic proximity Read ↗

Characterization of a transport and detoxification pathway for the antitumour drug bleomycin in Saccharomyces cerevisiae.Semantic proximity Read ↗

Rapid Identification of Chemoresistance Mechanisms Using Yeast DNA Mismatch Repair Mutants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.